We studied the infection rate of long-term intravenous access used for daily home treatment of cytomegalovirus (CMV) disease in 61 AIDS patients who had 75 central venous catheters implanted for antiviral maintenance therapy between February 1989 and December 1994. In 39 patients (64%) the risk factor for AIDS was intravenous drug abuse. Sixty-three catheters were Hickman type and 12 were totally implanted ports. The cumulative follow-up time was 19 000 catheter-days (52 patient-years), with median duration of placement of 249 days. The infection rate was 0.22 infections per 100 catheter days. The probability of remaining free of catheter-related sepsis was 58% at 6 months. In 25 cases (61%) antimicrobial therapy without catheter removal was successful. Three patients died because of a catheter-related infection (mortality rate 7.3%). Infection-free survival time was not related to the risk factor for AIDS (p = 0.44) or type of device (p = 0.41). The total infection rate in these patients receiving daily home maintenance therapy for CMV disease through a long-term catheter was similar to that in other AIDS patients receiving weekly treatment in hospital facilities.
Introduction
Intravenous maintenance treatment in patients with acquired immunodeficiency syndrome (AIDS) is frequently necessary, especially for cytomegalovirus (CMV) end-organ disease that requires daily intravenous therapy. 1 Indwelling long-term central venous catheters (CVCs) are increasingly being used in these patients, either Hickman-type tunnelled right atrial catheters 2 or totally implantable venous access devices. 3 These catheters allow long-term home therapy for patients with AIDS, improving their quality of life. Earlier studies reported a higher frequency of infectious complications of CVCs in AIDS patients when compared with control populations with these long-term CVCs, which were attributed to impairment of B-cell immunity. 4 However, these infection rates may not always be comparable due to differences in the type of device, in the use or care of the catheter and in the definitions applied for the diagnosis of infectious complications.
We report our experience with indwelling CVCs in an AIDS population with a predominantly low educational level and a high prevalence of former intravenous drug abuse, in which daily drug administration was performed at home by the patient or with the aid of the family.
Methods
Between February 1989 and December 1994, 82 CVCs were implanted in 66 AIDS patients at our hospital. Seven catheters were finally not included in the study: five due to implantation complications requiring catheter removal in the first 5 days (pneumothorax in one, malfunction in four), one due to lack of adequate information, and the last being used to receive chemotherapy for non-Hodgkin's lymphoma.
The remaining 75 indwelling CVCs of 61 AIDS patients were reviewed. CVCs used were of two types: totally implanted subcutaneous reservoirs (ports) and tunnelled Hickman-type catheters with one or two lumens. All patients had been diagnosed with CMV retinitis, with the exception of one patient who had CMV colitis. In 23 additional patients with CMV organ disease, no CVC was placed because of patient's refusal, moribund condition or uncontrolled intravenous drug abuse. CVCs were inserted during hospital admission by different surgeons in the operating theatre under aseptic conditions and with local anaesthesia; a few Hickman CVCs were percutaneously implanted by a vascular radiologist. Antibiotic prophylaxis was not used. 5 Before hospital discharge, a senior nurse instructed the patient or family in the catheter care, with emphasis on aseptic manipulation of the hub and connections. 6 Gancyclovir or foscarnet infusions were administered at home, once-aday for maintenance therapy, and twice or three times a day during relapses. The catheters were frequently used for blood sampling, transfusions, and for administration of other therapies when indicated. The patients were followed periodically, and all medical problems were managed in our unit. Patients charts were analysed for demographic data, type of device, time to first infection, duration (number of days that CVCs were in place until removal, death or last follow-up), evidence of CVCassociated infection, organisms isolated, and survival. The patients were classified as of low educational level when they had not achieved more than primary studies. For infections, we used the following definitions, modified from Press 7 et al.: Exit site infection, purulence in the skin exit of the catheter, with positive culture of the exudate; tunnel infection, erythema, tenderness and induration along the subcutaneous tract of the CVC; catheter-related sepsis or bacteraemia, physical signs of sepsis (fever >38.5 °C, rigors or hypotension), with positive blood cultures obtained from the catheter and a peripheral vein, and without other recognizable site of infection; cure, resolution of bacteraemia and recovery of physical signs of sepsis for at least 7 days after antibiotics had been discontinued. Blood cultures were drawn in all patients with fever or suspected catheter infection, simultaneously through the catheter and by peripheral vein puncture and processed with the BACTEC NR660 system. CVC-related bacteraemias were initially managed with intravenous antibiotics. If fever or bacteraemia persisted after more than 3 days of adequate therapy, or in case of relapse, the catheter was removed. Antibiotic therapy was maintained for at least 14 days, and daily antibiotic-heparin lock with gentamicin or tobramicin was used.
Statistical analysis
Time to first infection and catheter days in situ were calculated by the product-limit (Kaplan-Meier) method and comparisons were analysed by the logrank test.
Results

Patients
The charts of 61 AIDS patients with CMV disease with 75 CVCs were reviewed. There were 48 men and 13 women, with a mean age of 32.2 years (range 24-48). The predominant risk factors for AIDS were intravenous drug abuse in 39 patients (64%), and homosexuality in 15 (25%). Forty-eight (79%) patients were classified as of low cultural level. CMV disease was the first AIDS criterion in 20 patients (33%). Mean CD4 cell count at time of CMV diagnosis was 24/pJ (range 3-112). Non-medical intravenous drug use was not detected in any of the patients during follow-up.
Catheter infections
Sixty-three (84%) CVCs were Hickman, and 12 (16%) were Port-a-Cath. The total number of catheter days was 19 000, with a median duration time of 249 days (range 29-937). Kaplan-Meier estimates of CVC longevity at 3, 6 and 12 months were 86%, 63% and 25%, respectively (Figure 1 ). Of the 75 CVCs in use, 30 (40%) were infected; 23 had only one infection, four had two infections, two had three infections and one had four infections. These 41 infections yielded a rate of 0.22 infections/100 catheter-days, with a median time to first infective episode of 130 days (range 5-400 days). The median infection-free time after catheter placement was 207 days, and the probabilities of remaining free of catheter-related infection at 3, 6 and 12 months were 79%, 58% and 16%, respectively ( Figure 2) . Fifty (66.6%) catheters remained in place until the patient's death and 17 (22.6%) had to be removed, 13 (17.3%) because of sepsis and four (5.3%) because of mechanical problems (obstruction or breakage). At the end of the study, eight patients remained alive with a patent CVC on maintenance antiviral therapy.
Pathogens
Clinical features and outcome of the infection episodes are summarized in Table 1 . Gram-negative bacilli were isolated in 21 cases (51.2%) and Grampositive micro-organisms in 22 cases (53.6%). Six episodes were polymicrobial. Yeasts were isolated in only one episode. Most of the infections were catheter-related sepsis (36 cases) and no cases of septic thrombophlebitis were noted. Five exit site infections were diagnosed. Four were due to staphylococci which cured with antibiotic therapy alone, the other was caused by Pseudomonas aeruginosa, which despite appropriate antimicrobial therapy, spread to the subcutaneous tunnel and necessitated the catheter removal. Antimicrobial therapy was successful without removing the CVC in 25 cases (61%). There was no statistical difference between the cure rates for Gram-positive and Gramnegative infections (67% and 62%, respectively, p = 0.91). In 13 cases (31.7%) the catheter was withdrawn because of infection, and three additional patients died due to catheter-related sepsis, one of them with a methicillin-resistant S. aureus strain (mortality rate 7.3%). There was no significant difference in infection-free survival between those with Hickman CVCs and those with Port-a-Cath (p = 0.41), and no differences between the patients with or without antecedent intravenous drug abuse (p = 0.44). 
Discussion
Home therapy is an excellent therapeutic option in AIDS patients with CMV disease who require daily intravenous antiviral maintenance therapy. It combines the efficacy of drug treatment with a better quality of life by avoiding frequent visits to day-care hospital facilities. However, the risk of catheter complications, especially serious infections, has questioned its safety and usefulness. We report our experience with indwelling CVCs for home daily therapy in an AIDS population with a high prevalence of previous intravenous drug abuse and a predominantly low educational level. In our series drug infusions were managed by the patient himself or by family members, after adequate training. The increased risk of bacterial infections in AIDS patients when compared with the general population was recognized during the first years of the epidemic. 8 Various reports highlighted the risk of CVC infection. 4 ' 9 Specific studies in this issue have shown a higher infection rate in AIDS patients with CVC when compared to other populations without AIDS. 4 ' 10 The infection rates are, however, dependent on several factors, such as the characteristics of the population, the adequacy of catheter care training, the type of device, the frequency of use and the criteria used for diagnosis of catheter-related infections. Our study was quite homogeneous in this concern, as all our patients received daily antiviral home therapy for CMV disease with long-term venous access. All were trained in catheter use by the same nurse, and all cases of catheter-related sepsis were confirmed with positive blood cultures. In a similar study, Stanley ef a/. 11 studied 72 CVCs in use for 11 622 days in AIDS patients receiving therapy for cytomegalovirus disease with an infection rate of 0.31 per 100 days of catheter use; however, both percutaneous and tunnelled CVCs were included in the study. Their infection rate for tunnelled catheters was 0.18 per 100 days of catheter use, which is similar to ours. Raviglione et al. 4 analysed 46 Hickman catheters in 44 AIDS patients during a one-year period, and they noted an infection rate of 0.47 infections per 100 catheter days, but with a higher proportion of early infections (median time to first infection 11 days), perhaps due to contamination during implantation. Similar rates of infection have been described in outpatient treatment. Van der Pilj and Frissen 12 showed an infection rate of 0.17 per 100 catheter days in 47 AIDS patients with totally implantable venous access devices, and a total of 9069 catheterdays, more than half receiving home therapy. However, they included in the study not only patients receiving CMV daily maintenance therapy, but also patients receiving other treatments, with fewer frequent intravenous infusions. Mukau ef a/. 13 Our study shows the largest sample size in HIVinfected patients when compared with previous reports. Although the total incidence of infections was rather high (40%), our total CVC-associated infection rate is similar to others reported, 11 " 15 despite their greater frequency of use (at least once-a-day).
The median duration of CVC in our patients (249 days) is the longest reported in the literature in AIDS patients. Although the number of totally implantable subcutaneous devices in our study was low, we were unable to find any difference in the risk of infection between Hickman or Port-a-Cath CVC type. Most of our patients had a low educational status, and many of them had been intravenous drug abusers, two features that make this population highly susceptible to bacterial infection. However, there were no significant differences in the rate of infection between patients with or without prior intravenous drug abuse, although all patients denied intravenous drug use after CVC placement. The influence of antiviral therapy in the rate of infection could not be assessed in our series; the patients received either foscarnet or gancyclovir depending on the tolerance and risk factors for renal or bone-marrow toxicity, and they were frequently switched to the other agent after the appearance of secondary effects or relapse.
Zidovudine was used in some patients according to haematological tolerance, and also could not be used for infection risk analysis. 
